TransCode Therapeutics, Inc.
RNAZ
Rank in Stocks
#32419
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to... TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B. TransCode also pursues several cancer-agnostic initiatives. These encompass TTX-RIGA, an RNA-based agent engineered to stimulate the RIG-I immune pathway within the tumor's immediate surroundings; TTX-CRISPR, a gene-editing platform utilizing CRISPR/Cas9 technology to correct or eradicate oncogenic genes within cancer cells; and TTX-mRNA, an innovative mRNA platform dedicated to creating cancer vaccines that incite powerful cytotoxic immune reactions against malignant cells. Established in 2016, TransCode Therapeutics is headquartered in Boston, Massachusetts.
Share Price
$1.54
Last synced: 2026-11-09
Market Cap
$1.63M
Change (1 day)
3.36%
Change (1 year)
-83.00%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade TransCode Therapeutics, Inc. (RNAZ)
Category
Healthcare
EPS for TransCode Therapeutics, Inc. (RNAZ)
EPS as of June 2026 TTM: $-50.69
According to TransCode Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-50.69. At the end of 2025 the company had an EPS of $-52.59, a decrease compared to its 2024 EPS of $-47.14.
EPS history for TransCode Therapeutics, Inc. from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-50.69 | -3.61% |
| 2025 | $-52.59 | 11.56% |
| 2024 | $-47.14 | -98.64% |
| 2023 | $-3.45K | -95.28% |
| 2022 | $-73.19K | 11,194.35% |
| 2021 | $-648.00 | 120.59% |
| 2020 | $-293.76 | 308.00% |
| 2019 | $-72.00 | -96.95% |
| 2018 | $-2.36K | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -130.89% |
US
|
|
| $-7.07 | -86.05% |
US
|
|
| $-5.29 | -89.56% |
AU
|
|
| $12.88 | -125.41% |
BE
|
|
| $21.56 | -142.53% |
NL
|
Questions about TransCode Therapeutics, Inc.'s earnings per share (EPS)
What is TransCode Therapeutics, Inc.'s earnings per share (EPS)?
TransCode Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-50.69, as of Jun 2026.
What was TransCode Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, TransCode Therapeutics, Inc.'s earnings per share (EPS) was $-52.59, compared with $-47.14 in 2024.
How has TransCode Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, TransCode Therapeutics, Inc.'s earnings per share (EPS) was highest in 2024 ($-47.14) and lowest in 2022 ($-73.19K).
How does TransCode Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
TransCode Therapeutics, Inc.'s earnings per share (EPS) ($-50.69) is lower than that of all 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.